Sort
23,748 grants matching “melanoma”
Clinical production of viral vectors for cancer gene therapy
$1,001,150Steven Feldman · Division Of Basic Sciences - Nci · ZIC · FY2015 · CA
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2020 · CA
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2020 · CA
Bifunctional T cell receptor based immunotherapeutics
$1,000,000Hing C. Wong · Altor Bioscience. Llc · R44 · FY2009 · CA
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
$1,000,000Rene Gonzalez · Trampoline Pharma, Inc. · R44 · FY2022 · CA
Fluorescein for Sentinel Lymph Node Detection
$1,000,000James M McGreevy · Vestan, Inc. · R42 · FY2011 · CA
Programming Metabolically Fit TILs for Immunotherapy
$1,000,000Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R42 · FY2024 · CA
University of New Mexico Cancer Center Support Grant
$1,000,000Cheryl L Willman · University Of New Mexico Health Scis Ctr · P30 · FY2020 · CA
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2018 · CA
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
$1,000,000Steven Isaacman · Nanometics, Llc · R44 · FY2023 · CA
Riluzole Prodrugs for Melanoma and ALS
$1,000,000Allen Bernard Reitz · Fox Chase Chemical Diversity Center, Inc · R44 · FY2019 · CA
OCULAR MELANOMA
$1,000,000Johns Hopkins University · U10 · FY2002 · EY
Programming Metabolically Fit TILs for Immunotherapy
$1,000,000Shikhar Mehrotra · Lipo-Immuno Tech, Llc · R42 · FY2023 · CA
Moffitt Cancer Center Support Grant
$1,000,000Thomas A Sellers · H. Lee Moffitt Cancer Ctr & Res Inst · P30 · FY2016 · CA
Non-invasive staging of Metastasis by Precision MRI
$1,000,000Yiting Xu · Inlighta Biosciences, Llc · R44 · FY2023 · CA
Development of GPER Agonists as Cancer Therapeutics
$1,000,000Tina Garyantes · Linnaeus Therapeutics, Llc · R44 · FY2019 · CA
SIRPant Technology for anti-Cancer Immunity
$1,000,000Nathanael McCurley · Sirpant Immunotherapeutics, Inc. · R42 · FY2023 · CA
A Phase 2, randomized, double-blind, 4-arm, multicenter study to demonstrate the efficacy and safety of topical dosage formulations of a prescription drug product for actinic keratosis
$1,000,000Steven Isaacman · Nanometics, Llc · R44 · FY2024 · CA
Next Generation Autologous TIL Cancer Therapy: Development of GMP manufacturing process
$1,000,000Richard C Duke · Trampoline Pharma, Inc. · R44 · FY2023 · CA
SIRPant Technology for anti-Cancer Immunity
$999,999Nathanael McCurley · Bobcatbio, Inc. · R42 · FY2024 · CA
Improving the Efficacy of Dendritic Cell Vaccines
$999,999Jacques F Banchereau · Baylor Research Institute · P01 · FY2006 · CA
Development of GIFT4: a B cell focused immunotherapy for cancer
$999,997Paul Guyre · Celdara Medical, Llc · R44 · FY2018 · CA
Development of LNS8801 for cutaneous melanoma patients who cannot tolerate immunotherapy
$999,960Tina Garyantes · Linnaeus Therapeutics Inc · R44 · FY2025 · CA
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.
$999,883Michael King Schultz · Viewpoint Molecular Targeting, Inc. · R44 · FY2021 · CA
GMP peptide manufacturing, pharmacology/toxicology, and scaled radionuclide production and validation for Pb-212 receptor targeted alpha-particle therapy clinical trials for metastatic melanoma.
$999,883Michael King Schultz · Viewpoint Molecular Targeting, Inc. · R44 · FY2020 · CA